<p>GeneDx（纳斯达克：WGS - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 从 “持有” 评级下调至 “卖出” 评级。</p>
<ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
<p>其他一些券商最近也对 WGS 发布了报告。富国银行重申了 “增持” 评级，并将 GeneDx 的目标股价从 155.00 美元下调至 75.00 美元。Weiss Ratings 在 1 月 21 日的研究报告中重申了 GeneDx 的 “卖出（d）” 评级。BTIG Research 在周二的研究报告中将 GeneDx 的目标股价从 170.00 美元下调至 90.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 2 月 24 日的研究报告中重申了 “增持” 评级，并将 GeneDx 的目标股价从 160.00 美元下调至 130.00 美元。最后，加拿大皇家银行在周二的研究报告中将 GeneDx 的目标股价设定为 75.00 美元，并给予该股票 “买入” 评级。六位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标股价为 96.43 美元。</p>
<p><strong>查看我们最新的 WGS 股票报告</strong></p>
<h2>GeneDx 股票上涨 0.7%</h2>
<ul>
<li>GeneDx：即使在 2024 年上涨 2700% 后，仍有上涨空间</li>
</ul>
<p>GeneDx 股票在周五开盘价为 40.77 美元。GeneDx 的 52 周低点为 32.21 美元，52 周高点为 170.87 美元。该公司的 50 日移动平均线为 68.65 美元，200 日移动平均线为 105.43 美元。该公司的速动比率为 2.34，流动比率为 3.09，债务与股本比率为 0.38。该公司的市值为 11.9 亿美元，市盈率为-15.21，贝塔值为 2.06。</p>
<p>GeneDx（纳斯达克：WGS - 获取免费报告）在 5 月 4 日星期一最后发布了季度财报。该公司报告每股收益（EPS）为（0.28 美元），低于分析师的共识预期（0.06 美元）22 美分。GeneDx 的股本回报率为 9.15%，净利润率为-17.58%。该公司在本季度的收入为 1.0225 亿美元，而分析师的预期为 1.1246 亿美元。在去年同期，该公司的每股收益为（0.23 美元）。作为一个整体，研究分析师预测 GeneDx 在当前财年将发布 0.75 美元的每股收益。</p>
<h2>内部活动</h2>
<p>在其他 GeneDx 新闻中，董事 Keith A. Meister 在 3 月 5 日星期四购买了 140,026 股该公司的股票。每股平均成本为 81.19 美元，总价值为 11,368,710.94 美元。收购后，该董事直接持有该公司 3,228,150 股股票，价值 262,093,498.50 美元。此次交易使其持股增加了 4.53%。该购买在向 SEC 的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Kevin Feeley 在 3 月 4 日星期三出售了 6,187 股 GeneDx 股票。每股平均售价为 78.61 美元，总交易额为 486,360.07 美元。交易完成后，首席财务官直接持有该公司 18,674 股股票，价值 1,467,963.14 美元。此次交易使其持股减少了 24.89%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 104,028 股公司股票，价值 7,377,165 美元。目前 29.60% 的股票由公司内部人士持有。</p>
<h2>对 GeneDx 的对冲基金看法</h2>
<p>一些机构投资者最近修改了他们对 WGS 的持股。Westfield Capital Management Co. LP 在第四季度将其在 GeneDx 的持股增加了 87.1%。Westfield Capital Management Co. LP 现在拥有 1,018,261 股该公司的股票，价值 132,435,000 美元，此前在该期间内又收购了 474,167 股。ARK Investment Management LLC 在第三季度购买了 GeneDx 的新头寸，价值 48,157,000 美元。Franklin Resources Inc.在第四季度将其在 GeneDx 的持股增加了 60.4%。Franklin Resources Inc.现在拥有 1,092,988 股该公司的股票，价值 142,154,000 美元，此前在上个季度又购买了 411,607 股。Invesco Ltd.在第四季度将其在 GeneDx 的持股增加了 59.2%。Invesco Ltd.现在拥有 786,466 股该公司的股票，价值 102,288,000 美元，此前在上个季度又购买了 292,394 股。最后，住友三井信托集团在第三季度购买了 GeneDx 的新头寸，价值 31,488,000 美元。61.72% 的股票由机构投资者和对冲基金持有。</p>
<h2>GeneDx 公司简介</h2>
<p>（获取免费报告）</p>
<p>GeneDx 是一家临床诊断公司，专注于罕见和遗传疾病的全面基因和基因组检测。该公司提供广泛的检测组合，包括靶向基因面板、全外显子组测序、全基因组测序和染色体微阵列分析。GeneDx 的实验室服务通过提供详细的变异解释和报告，支持对从罕见儿童疾病和遗传性癌症综合症到神经肌肉和代谢疾病等广泛病症的诊断。</p>
<p>GeneDx 成立于 2000 年，总部位于马里兰州盖瑟斯堡，旨在加速基因组发现向临床护理的转化。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 GeneDx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0dT?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0dT"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GeneDx 吗？</h2>
<p>在你考虑 GeneDx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 GeneDx 并不在名单上。</p>
<p>虽然 GeneDx 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>华尔街禅将 GeneDx（NASDAQ:WGS）的评级从 “持有” 下调至 “卖出”。其他券商也调整了他们的评级，富国银行将其目标价从 155 美元下调至 75 美元，而 BTIG 研究则设定了 90 美元的新目标。GeneDx 的股票开盘价为 40.77 美元，52 周区间为 32.21 美元至 170.87 美元。该公司报告的季度每股收益为（0.28 美元），未达到预期，收入为 1.0225 亿美元。内部交易活动包括董事 Keith A. Meister 的重大购买和首席财务官 Kevin Feeley 的出售</p>

<p>GeneDx (NASDAQ:WGS - Get Free Report) was downgraded by Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>GeneDx（纳斯达克：WGS - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 从 “持有” 评级下调至 “卖出” 评级。</p>
</div><ul>
<li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
</div><p>A number of other brokerages also recently issued reports on WGS. Wells Fargo &amp; Company reiterated an &#34;overweight&#34; rating and issued a $75.00 price target (down from $155.00) on shares of GeneDx in a research note on Tuesday. Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of GeneDx in a research note on Wednesday, January 21st. BTIG Research decreased their price target on shares of GeneDx from $170.00 to $90.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. Piper Sandler reiterated an &#34;overweight&#34; rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Finally, Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the stock a &#34;buy&#34; rating in a research note on Tuesday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $96.43.</p>
<div class="lb-trans"><p>其他一些券商最近也对 WGS 发布了报告。富国银行重申了 “增持” 评级，并将 GeneDx 的目标股价从 155.00 美元下调至 75.00 美元。Weiss Ratings 在 1 月 21 日的研究报告中重申了 GeneDx 的 “卖出（d）” 评级。BTIG Research 在周二的研究报告中将 GeneDx 的目标股价从 170.00 美元下调至 90.00 美元，并给予该公司 “买入” 评级。Piper Sandler 在 2 月 24 日的研究报告中重申了 “增持” 评级，并将 GeneDx 的目标股价从 160.00 美元下调至 130.00 美元。最后，加拿大皇家银行在周二的研究报告中将 GeneDx 的目标股价设定为 75.00 美元，并给予该股票 “买入” 评级。六位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标股价为 96.43 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on WGS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 WGS 股票报告</strong></p>
</div><h2>GeneDx Stock Up 0.7%</h2>
<div class="lb-trans"><h2>GeneDx 股票上涨 0.7%</h2>
</div><ul>
<li>GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play</li>
</ul>
<div class="lb-trans"><ul>
<li>GeneDx：即使在 2024 年上涨 2700% 后，仍有上涨空间</li>
</ul>
</div><p>Shares of GeneDx stock opened at $40.77 on Friday. GeneDx has a 52-week low of $32.21 and a 52-week high of $170.87. The company has a 50 day moving average of $68.65 and a 200 day moving average of $105.43. The company has a quick ratio of 2.34, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.19 billion, a P/E ratio of -15.21 and a beta of 2.06.</p>
<div class="lb-trans"><p>GeneDx 股票在周五开盘价为 40.77 美元。GeneDx 的 52 周低点为 32.21 美元，52 周高点为 170.87 美元。该公司的 50 日移动平均线为 68.65 美元，200 日移动平均线为 105.43 美元。该公司的速动比率为 2.34，流动比率为 3.09，债务与股本比率为 0.38。该公司的市值为 11.9 亿美元，市盈率为-15.21，贝塔值为 2.06。</p>
</div><p>GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million during the quarter, compared to analysts' expectations of $112.46 million. During the same quarter in the prior year, the firm earned ($0.23) EPS. As a group, research analysts forecast that GeneDx will post 0.75 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>GeneDx（纳斯达克：WGS - 获取免费报告）在 5 月 4 日星期一最后发布了季度财报。该公司报告每股收益（EPS）为（0.28 美元），低于分析师的共识预期（0.06 美元）22 美分。GeneDx 的股本回报率为 9.15%，净利润率为-17.58%。该公司在本季度的收入为 1.0225 亿美元，而分析师的预期为 1.1246 亿美元。在去年同期，该公司的每股收益为（0.23 美元）。作为一个整体，研究分析师预测 GeneDx 在当前财年将发布 0.75 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other GeneDx news, Director Keith A. Meister bought 140,026 shares of the business's stock in a transaction dated Thursday, March 5th. The shares were acquired at an average cost of $81.19 per share, with a total value of $11,368,710.94. Following the acquisition, the director directly owned 3,228,150 shares of the company's stock, valued at $262,093,498.50. The trade was a 4.53% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kevin Feeley sold 6,187 shares of GeneDx stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $78.61, for a total transaction of $486,360.07. Following the completion of the transaction, the chief financial officer directly owned 18,674 shares in the company, valued at $1,467,963.14. The trade was a 24.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 104,028 shares of company stock valued at $7,377,165 in the last ninety days. 29.60% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 GeneDx 新闻中，董事 Keith A. Meister 在 3 月 5 日星期四购买了 140,026 股该公司的股票。每股平均成本为 81.19 美元，总价值为 11,368,710.94 美元。收购后，该董事直接持有该公司 3,228,150 股股票，价值 262,093,498.50 美元。此次交易使其持股增加了 4.53%。该购买在向 SEC 的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Kevin Feeley 在 3 月 4 日星期三出售了 6,187 股 GeneDx 股票。每股平均售价为 78.61 美元，总交易额为 486,360.07 美元。交易完成后，首席财务官直接持有该公司 18,674 股股票，价值 1,467,963.14 美元。此次交易使其持股减少了 24.89%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 104,028 股公司股票，价值 7,377,165 美元。目前 29.60% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On GeneDx</h2>
<div class="lb-trans"><h2>对 GeneDx 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of WGS. Westfield Capital Management Co. LP increased its holdings in shares of GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company's stock valued at $132,435,000 after acquiring an additional 474,167 shares during the period. ARK Investment Management LLC purchased a new position in GeneDx in the 3rd quarter valued at $48,157,000. Franklin Resources Inc. grew its position in GeneDx by 60.4% in the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company's stock valued at $142,154,000 after buying an additional 411,607 shares during the last quarter. Invesco Ltd. grew its position in GeneDx by 59.2% in the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company's stock valued at $102,288,000 after buying an additional 292,394 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new position in GeneDx in the 3rd quarter valued at $31,488,000. 61.72% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近修改了他们对 WGS 的持股。Westfield Capital Management Co. LP 在第四季度将其在 GeneDx 的持股增加了 87.1%。Westfield Capital Management Co. LP 现在拥有 1,018,261 股该公司的股票，价值 132,435,000 美元，此前在该期间内又收购了 474,167 股。ARK Investment Management LLC 在第三季度购买了 GeneDx 的新头寸，价值 48,157,000 美元。Franklin Resources Inc.在第四季度将其在 GeneDx 的持股增加了 60.4%。Franklin Resources Inc.现在拥有 1,092,988 股该公司的股票，价值 142,154,000 美元，此前在上个季度又购买了 411,607 股。Invesco Ltd.在第四季度将其在 GeneDx 的持股增加了 59.2%。Invesco Ltd.现在拥有 786,466 股该公司的股票，价值 102,288,000 美元，此前在上个季度又购买了 292,394 股。最后，住友三井信托集团在第三季度购买了 GeneDx 的新头寸，价值 31,488,000 美元。61.72% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>GeneDx Company Profile</h2>
<div class="lb-trans"><h2>GeneDx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.</p>
<div class="lb-trans"><p>GeneDx 是一家临床诊断公司，专注于罕见和遗传疾病的全面基因和基因组检测。该公司提供广泛的检测组合，包括靶向基因面板、全外显子组测序、全基因组测序和染色体微阵列分析。GeneDx 的实验室服务通过提供详细的变异解释和报告，支持对从罕见儿童疾病和遗传性癌症综合症到神经肌肉和代谢疾病等广泛病症的诊断。</p>
</div><p>Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.</p>
<div class="lb-trans"><p>GeneDx 成立于 2000 年，总部位于马里兰州盖瑟斯堡，旨在加速基因组发现向临床护理的转化。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than GeneDx</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 GeneDx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0dT" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=WGS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GeneDx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GeneDx 吗？</h2>
</div><p>Before you consider GeneDx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 GeneDx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 GeneDx 并不在名单上。</p>
</div><p>While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GeneDx 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GeneDx (NASDAQ:WGS) Cut to "Sell" at Wall Street Zen

Market Beat

GeneDx

基因免疫&健康关怀 ETF - iShares

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

内克塔治疗

Cidara Therap

富国银行

Piper Sandler Cos

富兰克林资源

景顺投资管理

Sumitomo Mitsui Trust Holdings, Inc.

GeneDx - CW27

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

GeneDx（纳斯达克股票代码：WGS）在 Wall Street Zen 被下调至 “卖出” 评级